XIST, LINC00173, FBN1, COL1A1, COL5A1, and BGN were identified as key molecules in the network, which have potential diagnostic value and may be therapeutic targets for ARVC. This evidence concerns the gene COL1A1 and arrhythmogenic right ventricular cardiomyopathy.